title: Effect of topographical distribution of α-synuclein pathology on TDP-43 accumulation in Lewy body disease.
abstract: It has been reported that the development of TDP-43 pathology in cases of Lewy body disease (LBD) might be associated with the severity of tau pathology. However, the impact of α-synuclein pathology on TDP-43 accumulation in LBD remains unclear. To clarify whether α-synuclein pathology has an effect on TDP-43 accumulation, independent of tau pathology, we examined by immunohistochemistry 56 cases of LBD using a phosphorylation-dependent TDP-43 antibody. The frequency of TDP-43 pathology in all LBD cases was 18% (10/56). In 37 LBD cases with no or low tau burden (LBD-Ltau; Braak NFT stages 0-II), the frequency of TDP-43 pathology was 19% (7/37). The frequency of TDP-43 pathology in diffuse neocortical type LBD-Ltau cases was 36% (4/11), which was higher than those in limbic and brain stem-predominant types (11-14%). The amygdala and entorhinal cortex were the most frequently affected sites of TDP-43 pathology in LBD-Ltau cases. In LBD-Ltau cases, the proportion of diffuse neocortical type LBD was higher in the TDP-43-positive cases, than that in TDP-43-negative cases (57 vs. 23%). In all LBD cases, α-synuclein pathology in the temporal cortex was significantly more severe in TDP-43-positive cases, and significantly correlated with the severity of TDP-43 pathology in the amygdala. In a multivariate model, the presence of severe α-synuclein pathology was significantly associated with the development of TDP-43 pathology independent of age at death and tau pathology. In the amygdala, TDP-43 was often colocalized with α-synuclein or tau. Given these findings, we suggest that α-synuclein pathology is associated with TDP-43 accumulation in LBD cases.
authors.affiliation: Greater Manchester Neurosciences Centre, Hope Hospital, University of Manchester, Salford, UK.
authors.forename: Osamu
authors.initials: O
authors.lastname: Yokota
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Davidson
authors.forename: Tetsuaki
authors.initials: T
authors.lastname: Arai
authors.forename: Masato
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Akiyama
authors.forename: Hideki
authors.initials: H
authors.lastname: Ishizu
authors.forename: Seishi
authors.initials: S
authors.lastname: Terada
authors.forename: Stephen
authors.initials: S
authors.lastname: Sikkink
authors.forename: Stuart
authors.initials: S
authors.lastname: Pickering-Brown
authors.forename: David M A
authors.initials: DM
authors.lastname: Mann
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000679:Amygdala / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D001921:Brain / Q000378:metabolism* / Q000473:pathology* / Q000503:physiopathology; D018728:Entorhinal Cortex / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D020961:Lewy Body Disease / Q000378:metabolism* / Q000473:pathology* / Q000503:physiopathology; D008297:Male; D019579:Neocortex / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D051844:alpha-Synuclein / Q000378:metabolism*
chemical_list: D051844:alpha-Synuclein